Could Apricus Biosciences, Inc. (APRI) Lose Strenght? The Stock Increases A Lot Today

February 15, 2018 - By Louis Casey

The stock of Apricus Biosciences, Inc. (NASDAQ:APRI) is a huge mover today! The stock increased 14.04% or $0.3903 during the last trading session, reaching $3.1703. About 3.62 million shares traded or 553.84% up from the average. Apricus Biosciences, Inc. (NASDAQ:APRI) has declined 71.78% since February 15, 2017 and is downtrending. It has underperformed by 88.48% the S&P500.
The move comes after 5 months positive chart setup for the $48.24M company. It was reported on Feb, 15 by Barchart.com. We have $3.39 PT which if reached, will make NASDAQ:APRI worth $3.38M more.

Analysts await Apricus Biosciences, Inc. (NASDAQ:APRI) to report earnings on March, 12. They expect $-0.13 earnings per share, down 225.00 % or $0.09 from last year’s $-0.04 per share. After $-0.30 actual earnings per share reported by Apricus Biosciences, Inc. for the previous quarter, Wall Street now forecasts -56.67 % EPS growth.

Apricus Biosciences, Inc. (NASDAQ:APRI) Ratings Coverage

Among 6 analysts covering Apricus Bioscience Inc (NASDAQ:APRI), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Apricus Bioscience Inc had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Apricus Biosciences, Inc. (NASDAQ:APRI) has “Buy” rating given on Tuesday, January 16 by H.C. Wainwright. Ascendiant Capital Markets initiated Apricus Biosciences, Inc. (NASDAQ:APRI) on Thursday, August 13 with “Buy” rating. The firm has “Neutral” rating by Roth Capital given on Friday, November 6. The firm has “Outperform” rating given on Friday, November 6 by FBR Capital. The stock has “Neutral” rating by TH Capital on Friday, November 6. The firm has “Buy” rating by H.C. Wainwright given on Thursday, August 3. The rating was maintained by H.C. Wainwright on Friday, November 3 with “Buy”. The stock of Apricus Biosciences, Inc. (NASDAQ:APRI) has “Neutral” rating given on Wednesday, December 9 by Sterne Agee CRT. The firm earned “Buy” rating on Tuesday, September 5 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Wednesday, August 30.

More recent Apricus Biosciences, Inc. (NASDAQ:APRI) news were published by: Seekingalpha.com which released: “Another February Biotech Catalyst To Watch” on February 07, 2018. Also Gurufocus.com published the news titled: “Healthcare Value Capital, LLC Buys Apricus Biosciences Inc, Sells Pfizer Inc …” on January 23, 2018. Valuewalk.com‘s news article titled: “PhotoMedex, Inc. (PHMD) gets new 14.7% activist investor; Apricus Biosciences …” with publication date: January 31, 2018 was also an interesting one.

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. The company has market cap of $48.24 million. The Company’s lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. It has a 12.89 P/E ratio. The firm also engages in developing RayVa, which is in Phase 2 development for the treatment of RaynaudÂ’s Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.